Seize the first-line opportunity!
Roche is pleased to share the news of the FDA approval of POLIVY in combination with R-CHP for adult patients with previously-treated DLBCL. Polivy combination is the first FDA-approved therapy in nearly 20 years for the first-line treatment of DLBCL.
The FDA approval is based on the POLARIX study in which it was shown that POLIVY + R-CHP, compared to R-CHOP, was able to reduce the risk of disease progression, recurrence or death by 27%, while maintaining a similar safety profile.
This approval, as well as the prior approval of Pola-R-CHP by the European Commission, brings the total approvals of POLIVY in 1L DLBCL to 70 countries.
In addition, POLIVY is recommended in 1L DLBCL by the NCCN and by other national guidelines including in Germany, and has received NICE recommendation for use in the UK’s National Health System.